Rash with different types of BCR-ABL inhibitors in chronic myelogenous leukemia: a systematic review and meta-analysis

Papers of special note have been highlighted as: • of interest

References

• 1. Soverini S, De Benedittis C, Mancini M, Martinelli G. Best practices in chronic myeloid leukemia monitoring and management. Oncologist 21(5), 626–633 (2016).
  Medline CASGoogle Scholar
• 2. Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. J. Annal. Hematol. 94(Suppl. 2), 241–247 (2015).
  MedlineGoogle Scholar
• 3. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. J Am. J. Hematol. 93(3), 442–459 (2018).
  MedlineGoogle Scholar
• 4. Cortes J, Pavlovsky C, Saußele S. Chronic myeloid leukaemia. Lancet 398(10314), 1914–1926 (2021).
  Medline CASGoogle Scholar
• 5. NCCN. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia, version 3.2022. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf
  Google Scholar
• 6. Hochhaus A, Baccarani M, Silver RT et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4), 966–984 (2020).
  Medline CASGoogle Scholar
• 7. Chinese Society of Hematology, Chinese Medical Association. The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition). Chin. J. Hematol. 41(5), 353–364 (2020).
  Google Scholar
• 8. Macdonald JB, Macdonald B, Golitz LE, Lorusso P, Sekulic A. Cutaneous adverse effects of targeted therapies. Part I: inhibitors of the cellular membrane. J. Am. Acad. Dermatol. 72(2), 203–218 (2015).
  Medline CASGoogle Scholar
• 9. Jha P, Himanshu D, Jain N, Singh AK. Imatinib-induced Stevens–Johnsons syndrome. BMJ Case Rep. 2013, DOI: 10.1136/bcr-2012-007926 (2013).
  MedlineGoogle Scholar
• 10. Avila-Castano K, Morgenstern-Kaplan D, Carrillo-Martin I, Gonzalez-Estrada A. Bosutinib-induced Stevens–Johnson syndrome and evidence of tolerance to a structurally dissimilar tyrosine kinase inhibitor. Cureus 14(3), e23288 (2022).
  MedlineGoogle Scholar
• 11. Nagai T, Karakawa M, Komine M, Muroi K, Ohtsuki M, Ozawa K. Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment. Eur. J. Haematol. 91(3), 270–272 (2013).
  MedlineGoogle Scholar
• 12. Woo SM, Huh CH, Park KC, Youn SW. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J. Dermatol. 34(10), 724–726 (2007).
  MedlineGoogle Scholar
• 13. Dickens E, Lewis F, Bienz N. Imatinib: a designer drug, another cutaneous complication. Clin. Exp. Dermatol. 34(5), 603–604 (2009).
  Medline CASGoogle Scholar
• 14. Cheng H, Geist DE, Piperdi M, Virk R, Piperdi B. Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour. Australas. J. Dermatol. 50(1), 41–43 (2009).
  MedlineGoogle Scholar
• 15. Shimizu K-I, Kuroda H, Kida M et al. [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia]. Rinsho Ketsueki 46(10), 1152–1155 (2005).
  MedlineGoogle Scholar
• 16. Cortes JE, Kantarjian H, Shah NP et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 367(22), 2075–2088 (2012).
  Medline CASGoogle Scholar
• 17. Mehra N, Varmeziar A, Chen X et al. Cross-domain text mining to predict adverse events from tyrosine kinase inhibitors for chronic myeloid leukemia. Cancers (Basel) 14(19), 4686 (2022).
  Medline CASGoogle Scholar
• 18. Drucker AM, Wu S, Busam KJ, Berman E, Amitay-Laish I, Lacouture ME. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. Eur. J. Haematol. 90(2), 142–150 (2013).
  Medline CASGoogle Scholar
• 19. Cortes JE, Kim DW, Kantarjian HM et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J. Clin. Oncol. 30(28), 3486–3492 (2012). • During subgroup analysis of all grades of rash, there were more rash cases in the bosutinib group than in the imatinib group.
  Medline CASGoogle Scholar
• 20. Radich JP, Kopecky KJ, Appelbaum FR et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 120(19), 3898–3905 (2012).
  Medline CASGoogle Scholar
• 21. Hughes TP, Lipton JH, Spector N et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood 124(5), 729–736 (2014). • Analysis of the literature suggested that all grades of rash was higher in nilotinib group compared with imatinib.
  Medline CASGoogle Scholar
• 22. Jabbour E, Kantarjian HM, Saglio G et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123(4), 494–500 (2014).
  Medline CASGoogle Scholar
• 23. Hjorth-Hansen H, Stenke L, Söderlund S et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur. J. Haematol. 94(3), 243–250 (2015).
  Medline CASGoogle Scholar
• 24. Wang J, Shen ZX, Saglio G et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood 125(18), 2771–2778 (2015). • Analysis of the literature suggested that all grades of rash was higher in nilotinib group compared with imatinib.
  Medline CASGoogle Scholar
• 25. Lipton JH, Chuah C, Guerci-Bresler A et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 17(5), 612–621 (2016). • In subgroup analysis of all grades of rash, the ponatinib group had a higher incidence of rash than the imatinib group.
  Medline CASGoogle Scholar
• 26. Kwak JY, Kim SH, Oh SJ et al. Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clin. Cancer Res. 23(23), 7180–7188 (2017).
  Medline CASGoogle Scholar
• 27. Cortes JE, Gambacorti-Passerini C, Deininger MW et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J.Clin. Oncol. 36(3), 231–237 (2018). • During subgroup analysis of all grades of rash, there were more rash cases in the bosutinib group than in the imatinib group.
  Medline CASGoogle Scholar
• 28. Cortes JE, Jiang Q, Wang J et al. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia 34(8), 2064–2073 (2020).
  Medline CASGoogle Scholar
• 29. Zhang L, Meng L, Liu B et al. Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: a phase iii, randomized, open-label, multi-center FESTnd study. Clin. Cancer Res. 27(1), 70–77 (2021).
  MedlineGoogle Scholar
• 30. Hochhaus A, Saglio G, Hughes TP et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5), 1044–1054 (2016). • Analysis of the literature suggested that all grades of rash was higher in nilotinib group compared with imatinib.
  Medline CASGoogle Scholar
• 31. Hochhaus A, Larson RA, Guilhot F et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N. Engl. J. Med. 376(10), 917–927 (2017).
  Medline CASGoogle Scholar
• 32. Ciftciler R, Haznedaroglu IC. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. Eur. Rev. Med. Pharmacol. Sci. 25(24), 7787–7798 (2021).
  Medline CASGoogle Scholar
• 33. Pretel-Irazabal M, Tuneu-Valls A, Ormaechea-Pérez N. Adverse skin effects of imatinib, a tyrosine kinase inhibitor. Actas Dermosifiliogr. 105(7), 655–662 (2014).
  Medline CASGoogle Scholar
• 34. Musolino C, Allegra A, Mannucci C et al. Possible role of interleukin-31/33 axis in imatinib mesylate-associated skin toxicity. Turk. J. Haematol. 32(2), 168–171 (2015).
  MedlineGoogle Scholar
• 35. Peng N, Dou XL, Yu L et al. Clinical characteristics, treatment pattern, and outcomes in newly diagnosed patients with chronic myeloid leukemia in the chronic phase by age. Chin. J. Hematol. 42(2), 101–108 (2021).
  CASGoogle Scholar